NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Ocugen, Inc. (OCGN) Stock Analysis

Ocugen, Inc. (OCGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OCGN

$0.82

+$0.00 (+0.32%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OCGN with… →

OCGN Key Statistics

As of Oct 21, 2026
Trading
Open
$0.83
Previous Close
$0.81
Day's Range
0.79–0.83
52-Week Range
0.78–2.73
Volume
4.30M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.27
Valuation
Market Cap
$276.41M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
60.34
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.26
Financials (FY)
Revenue (FY)
$4.41M+8.83%
Net Income (FY)
−$67.85M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
339.11M
1-Year Return
−48.08%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
6.17M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OCGN closed at $0.82, −48.08% over 1 year.

Ocugen, Inc. (OCGN) has a market capitalization of $276.41M.

In fiscal 2025, OCGN reported revenue of $4.41M.

OCGN Stock Return by Calendar Year

Ocugen, Inc. (OCGN) 10-year return: what $10,000 became

1 year
$10,000 $5,192
−48.08%
5 years
$10,000 $963
−90.37%
10 years
$10,000 $51
−99.49%

If you had invested $10,000 in Ocugen, Inc. (OCGN) 10 years ago, at the close on October 21, 2016, it would have been worth $51 at the close on October 21, 2026: −99.49% in total, −41.00% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.62%
2025+67.70%
2024+40.00%
2023−55.77%
2022−71.43%
2021+148.63%
2020+251.92%
2019−90.15%
2018−95.71%
2017+22.75%
2016 (partial year)−18.54%

As of October 21, 2026.

OCGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.41M−$67.85M−1,537.4%
2024$4.06M−$54.05M−1,333.0%
2023$6.04M−$63.08M−1,045.0%
2022$2.49M−$86.80M−3,488.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.41M—−$62.92M−$67.85M−1,537.4%
2024$4.06M—−$54.76M−$54.05M−1,333.0%
2023$6.04M—−$65.53M−$63.08M−1,045.0%
2022$2.49M—−$89.07M−$86.80M−3,488.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OCGN Valuation vs Biotechnology Median

Median of 608 stocks
MetricOCGNBiotechnology medianvs median
P/S ratio60.3413.304.5x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ocugen, Inc. (OCGN) is capitalised at $276.41M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 116 employees.

The 52-week range on file runs from $0.78 to $2.73. The most recent close on file for OCGN is $0.82, dated October 21, 2026. That is $0.00 (+0.32%) against the previous close. The latest close sits 4.5% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.41M. That is +8.83% against the prior fiscal year, when revenue was $4.06M. The same year closed with a net loss of $67.85M. Trailing earnings per share are −0.26.

Across the 4 fiscal years on file, revenue moves from $2.49M in 2022 to $4.41M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 60.34. On price-to-sales that is 4.5 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −48.08%. Measured over 10 years, that is −41.00% a year compounded. The reported beta is 2.27. Annualized volatility over the trailing 10 years is 165.84%.

Growth & Income

No dividend is on file for OCGN.

2026 is still running; the total return is −39.62% year to date. Across the complete calendar years on file, 2020 returned +251.92% and 2018 returned −95.71%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Ocugen, Inc. (OCGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ocugen, Inc. OCGN $276.41M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ocugen, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ocugen, Inc.

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Visit website →